Filing Flows › BeOne Medicines (ONC) › Guidance history
BeOne Medicines (ONC) guidance history: what it guided and what it reported
BeOne Medicines gave guidance in 8 earnings releases on file since Feb 27, 2025. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 1 of 1, on average +3.7% against the guided midpoint. Its releases raised guidance 3 times and lowered it 0 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $6.2B–$6.4B (Feb 26, 2026) → raised $6.3B–$6.5B (May 6, 2026) → raised $6.6B–$6.8B (Aug 5, 2026) → raised $6.9B–$7.0B (Nov 5, 2026) | — | to be reported | — |
| FY2025 | $4.9B–$5.3B (Feb 27, 2025) → reaffirmed $4.9B–$5.3B (May 7, 2025) → reaffirmed $4.9B–$5.3B (Aug 6, 2025) → raised $5.0B–$5.3B (Nov 6, 2025) | $5.3B | above the range | +3.8% |
GAAP gross margin
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 80.0% (Feb 26, 2026) → reaffirmed 80.0% (May 6, 2026) → reaffirmed 80.0% (Aug 5, 2026) → reaffirmed 80.0% (Nov 5, 2026) | — | to be reported | — |
| FY2025 | 80.0% (Feb 27, 2025) → reaffirmed 80.0% (May 7, 2025) → reaffirmed 80.0% (Aug 6, 2025) → lowered -80.0% (Nov 6, 2025) | 87.5% | above the range | +167.5 pts |
GAAP operating expenses
Met or beat 1 of 1 periods (0 above, 1 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $4.1B–$4.4B (Feb 27, 2025) → reaffirmed $4.1B–$4.4B (May 7, 2025) | $4.2B | within the range | -0.5% |
Operating expenses
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $4.1B–$4.4B (Aug 6, 2025) → reaffirmed $4.1B–$4.4B (Nov 6, 2025) | — | — | — |
Other income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $25.0M–$50.0M (Feb 26, 2026) → reaffirmed $25.0M–$50.0M (May 6, 2026) → reaffirmed $25.0M–$50.0M (Aug 5, 2026) → reaffirmed $25.0M–$50.0M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
Questions
Does BeOne Medicines beat its guidance?
BeOne Medicines gave guidance in 8 earnings releases on file since Feb 27, 2025. Of 3 guided periods since reported, it met or beat its own guidance 3 times (100%). Revenue: 1 of 1, on average +3.7% against the guided midpoint.
How often does BeOne Medicines raise guidance?
Its earnings releases raised guidance 3 times and lowered it 0 times since Feb 27, 2025.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.